A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome — Stella

Recruiting

Back to Angelman Syndrome trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

United States

Cedars-Sinai Medical Center, Los Angeles, California

Rush University Medical Center, Chicago, Illinois

Boston Children's Hospital, Boston, Massachusetts

Key details

Phase

Early testing / Safety & dosing

Sponsor

MavriX Bio, LLC

Enrollment target

~12 participants

Started

October 2025

Primary completion

March 2028

Age range

4 Years – 50 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov